Clinical Trial

A Study of IBI363 in Subjects With Advanced Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Protocol Amendment History 3 changes
notable Enrollment increased: 150 -> 180 participants 2026-07-30
notable Primary completion pushed: 2025-06-06 -> 2028-10-19 2026-07-30
minor Completion pushed: 2026-07-31 -> 2028-10-19 2026-07-30
Trial Details
NCT Number NCT06081920
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Melanoma
Enrollment 180 participants
Start Date 2023-10-19
Primary Completion 2028-10-19 (estimated)
Study Completion 2028-10-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-29